Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Teva Pharmaceutical Industries Limited · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

There has not been any material change in our assessment of market risk as set forth in Part II, Item 7A to our Annual Report on Form 10-K for the year ended December 31, 2025.